lemborexant + Placebo

Phase 3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Insomnia Disorder

Conditions

Insomnia Disorder

Trial Timeline

Nov 15, 2016 → Jan 8, 2019

NCT ID

NCT02952820

About lemborexant + Placebo

lemborexant + Placebo is a phase 3 stage product being developed by Eisai for Insomnia Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT02952820. Target conditions include Insomnia Disorder.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07384429	Approved	Recruiting	Mar 19, 2026	Dec 1, 2026	Parkinson's Disease
NCT06874855	Approved	Recruiting	Mar 13, 2023	May 31, 2027	Delayed Sleep Phase Syndrome
NCT04549168	Phase 3	Completed	Nov 6, 2020	Mar 17, 2023	Sleep Initiation and Maintenance Disorders
NCT02952820	Phase 3	Completed	Nov 15, 2016	Jan 8, 2019	Insomnia Disorder

Competing Products

20 competing products in Insomnia Disorder

See all competitors

Product	Company	Stage	Hype Score
ACT-541468 5 mg + ACT-541468 10 mg + ACT-541468 25 mg + Zolpidem + Placebo 1 + Placebo 2	Idorsia	Phase 2	47
Zolpidem (Myslee®) + placebo	Astellas Pharma	Approved	85
zolpidem	Astellas Pharma	Approved	85
Mirtazapine Tablets	Sun Pharmaceutical	Approved	85
Lemborexant (LEM) 5 mg (Z-Drug-mono cohort) + Lemborexant (LEM) 5 mg (SUV-mono cohort) + Lemborexant (LEM) 5 mg (SUV-combination cohort) + Lemborexant (LEM) 5 mg (RMT-combination cohort)	Eisai	Approved	85
E2006 1.0 mg + E2006 2.5 mg + E2006 5.0 mg + E2006 10.0 mg + E2006 25.0 mg + E2006 50.0 mg + E2006 100 mg + E2006 200 mg + Zolpidem 10 mg + E2006 Matched Placebo or Zolpidem Matched Placebo + E2006 Matched Placebo	Eisai	Phase 1	33
Lemborexant 5 mg + Lemborexant 10 mg + Lemborexant-matched placebo. + Flurazepam 30 mg	Eisai	Phase 1	33
E2006	Eisai	Phase 1	33
Lemborexant + Lemborexant + Lemborexant-matched placebo + Zolpidem tartrate + Zolpidem-matched placebo	Eisai	Phase 3	77
LEM 5 mg + LEM 10 mg	Eisai	Phase 3	77
Eszopiclone	Eisai	Pre-clinical	23
Eszopiclone 1 mg + Eszopiclone 2 mg + Eszopiclone 3 mg + Placebo + Zolpidem Tartrate 10 mg	Eisai	Phase 2/3	65
E2006 + Placebo	Eisai	Phase 2	52
Zolpidem tablets + Suvorexant tablets, over-encapsulated + Lemborexant tablets + Placebo lemborexant + Placebo zolpidem + Placebo suvorexant	Eisai	Phase 1	33
Eszopiclone	Eisai	Pre-clinical	23
Eszopiclone 1 mg- Elderly + Eszopiclone 2 mg- Elderly + Eszopiclone 3 mg- Non-elderly + Eszopiclone 2 mg- Non-elderly	Eisai	Phase 3	77
Eszopiclone 3 mg + Eszopiclone 1 mg	Eisai	Phase 1	33
LY2624803	Eli Lilly	Phase 1	33
LY2624803 - Capsules + Zolpidem - Tablets + Placebo - Capsules + Placebo - Tablets	Eli Lilly	Phase 1	33
LY2624803	Eli Lilly	Phase 1	33

Other Products from Eisai

MecobalaminApproved

MonteplaseApproved

E2020 + PlaceboApproved

Palonosetron 0.075 mg IV + Dexamethasone 10 mg IV + Promethazine 25 mg IVApproved

DonepezilApproved